Alphabet Inc Class A vs Medpace Holdings Inc — how do they compare? Alphabet Inc Class A trades at $344.2 (market cap $4.20T), while Medpace Holdings Inc trades at $598 (market cap $16.90B). The key difference: Alphabet Inc Class A is far larger — about 248.5× Medpace Holdings Inc's market cap, and Alphabet Inc Class A pays a 0.26% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| GOOGL | MEDP | |
|---|---|---|
Market Cap | $4.20T | $16.90B |
Sector | Media | Technology |
52-Week High | $402.62 | $620.59 |
52-Week Low | $199.32 | $393.42 |
Enterprise Value | $4.09T | $16.52B |
Dividend Yield | 0.26% | — |
Signals from Pluang's Aura AI — not financial advice
Alphabet (GOOGL) is trading at $343.80, down 3.84% amid broader tech sector rotation. Despite the recent decline, the company maintains strong fundamentals with 2025 revenue of $402.84B and net income of $132.17B, representing a 32.8% profit margin. Technical indicators show bearish momentum with the stock testing support near $341, while analyst consensus remains overwhelmingly bullish with an 85% buy rating and $426.28 price target. Recent quarterly earnings have consistently exceeded expectations, with Q2 2026 EPS of $9.11 beating estimates by 217%.
The outlook remains positive given Alphabet's dominant market position, AI leadership, and strong cash flow generation. Key risks include antitrust scrutiny and tech sector volatility. With the stock trading below consensus targets and showing robust earnings growth, current levels present a potential entry point for long-term investors seeking exposure to AI and digital advertising growth.
MEDP trades at $596.98, down 0.9% on the day but near its 52-week highs. The stock shows strong technical momentum with bullish moving averages and recent golden cross formation. Fundamentally, the company delivered three consecutive quarterly earnings beats with Q2 2026 EPS of $4.25 beating expectations of $3.98. Revenue growth remains robust at 17.2% year-over-year in Q2 2026, supported by record net bookings and a $3.0 billion backlog.
MEDP presents a growth story with strong fundamentals but trades at premium valuations (P/E 35.58, P/S 6.27). The primary investment opportunity lies in continued execution on record bookings and backlog conversion. Key risks include the ongoing shareholder litigation investigation and potential valuation compression if growth moderates. Analyst consensus targets $599.57 with 21% buy ratings, suggesting limited near-term upside from current levels.
Trailing returns across standard periods
Latest headlines on both assets
Alphabet, the parent company of Google, earns nearly 90% of its revenue from Google services, mainly through advertising. Other revenue comes from subscriptions (YouTube TV, YouTube Music), platform sales (Play Store purchases), and devices (Pixel, Chromebooks, Chromecast). Google Cloud contributes around 10%, while investments in self-driving cars (Waymo), health (Verily), and internet access (Google Fiber) make up the rest.
Read more on GOOGL →Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →